CXCR4 and lung cancer: Indeed, in preclinical studies, it was demonstrated that neutralization of SDF-1 by an anti-SDF-1 or anti-CXCR4 monoclonal antibody resulted in a significant decrease of lung cancer metastases [38, 39].